Ionis, AstraZeneca's polyneuropathy med improved patients' quality of life in phase 3, teeing up battle with Alnylam

Ionis and AstraZeneca are finally cracking open the hood to phase 3 data of eplontersen, a burgeoning competitor to Alnylam’s ATTR polyneuropathy franchise.

Eplontersen stymied disease progression as measured by the Neuropathy Impairment Score +7, with a 0.28 point LS mean increase compared to a 25.06 point increase for patients on placebo. Treated patients also reported an improvement in a quality of life questionnaire